<DOC>
	<DOCNO>NCT00325260</DOCNO>
	<brief_summary>In study Influvac compare Agrippal , another subunit influenza vaccine already market China . The main objective study show vaccine comparable regard efficacy . In addition , safety efficacy data Influvac assess Chinese population .</brief_summary>
	<brief_title>Non-Inferiority Study Comparing Subunit Vaccines Influvac Agrippal China</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>sign date informed consent healthy mental health enough understand study , inform consent form questionnaire know allergic constituent vaccine autoimmune disorder , take immunomodulating drug immune disfunction secondary HIV document serious adverse reaction previous influenza vaccination document influenza infection vaccination six month prior start study receive vaccine , immunoglobulins investigational drug month prior start study</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>influenza</keyword>
	<keyword>non-inferiority</keyword>
	<keyword>Influvac</keyword>
	<keyword>Agrippal</keyword>
	<keyword>healthy subject</keyword>
</DOC>